Overview A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients Status: Completed Trial end date: 2013-07-23 Target enrollment: Participant gender: Summary The purpose of this study was to evaluate the safety and efficacy of mirabegron as add-on therapy in patients with OAB treated with solifenacin. Phase: Phase 4 Details Lead Sponsor: Astellas Pharma IncTreatments: MirabegronSolifenacin Succinate